These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34181760)

  • 41. On the coherence of model-based dose-finding designs for drug combination trials.
    Park Y; Liu S
    PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A latent contingency table approach to dose finding for combinations of two agents.
    Yin G; Yuan Y
    Biometrics; 2009 Sep; 65(3):866-75. PubMed ID: 18759848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose finding studies for therapies with late-onset toxicities: A comparison study of designs.
    Barnett H; Boix O; Kontos D; Jaki T
    Stat Med; 2022 Dec; 41(30):5767-5788. PubMed ID: 36250912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
    Lin R; Yuan Y
    Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes.
    Jin H; Yin G
    Pharm Stat; 2023; 22(5):773-783. PubMed ID: 37095681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
    Chen Z; Krailo MD; Sun J; Azen SP;
    Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Data-dependent early completion of dose-finding trials for drug-combination.
    Kojima M
    Stat Methods Med Res; 2023 Apr; 32(4):820-828. PubMed ID: 36775992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hybrid continuous reassessment method with overdose control for safer dose escalation.
    Ghosh D; Xie H; Zhang L; Chen F; Mohanty S; Li X
    J Biopharm Stat; 2023 Sep; 33(5):586-595. PubMed ID: 36715485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
    Zhang D; Xu J
    Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.